Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell Lymphomas

This is an investigator-initiated, open-label, single-arm, multicenter, Phase II clinical study. The study is designed to evaluate the safety and potential effectiveness of glofitamab in adults with their disease, diffuse large B-cell lymphoma (DLBCL has either not responded to initial treatment or has returned after an initial response and who are eligible and medically fit for autologous stem cell transplantation (ASCT). Autologous stem cell transplantation is a commonly used treatment in this situation and involves high-dose chemotherapy followed by infusion of your own stem cells, which ar

Trial Details

NCT ID
NCT07387848
Phase
PHASE2
Sponsor
American University of Beirut Medical Center
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Glofitamab
Locations (sample)
  • Beirut, Lebanon|33.89332,35.50157

Key Eligibility Criteria

  • \- To be eligible to participate in this trial, an individual must meet all of the following criteria:
  • Provision of signed and dated informed consent form (ICF) ) by the patient/impartial witness/legal representative before any trial related procedures.
  • Male or female aged between 18 and 65 years.
  • Ability and willingness to comply with the study protocol.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →